[시장보고서]세계의 면역 단백질 진단 검사 시장(2023-2030년)

세계의 면역 단백질 진단 검사 시장(2023-2030년)

Global Immunoprotein Diagnostic Testing Market - 2023-2030

상품코드 : 1345425

리서치사 : DataM Intelligence

발행일 : 2023년 09월

페이지 정보 : 영문 195 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,350

￦ 6,069,000

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 6,767,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 10,953,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

개요

면역 단백질 진단 검사(Immunoprotein Diagnostic Testing) 시장은 2022년에 94억 달러에서, 2023-2030년 예측 기간 동안 CAGR 6.9%로 성장하여 2030년에는 158억 달러에 이를 것으로 예측됩니다.

면역 단백질 진단 검사는 면역글로불린과 예비알부민과 같은 특정 단백질을 분석하기 위해 체내 면역단백질의 수준을 검출하는 진단 절차입니다. 지속적인 기술 개발로 면역단백질 진단검사 시장은 세계적으로 활황을 보이고 있습니다. 이러한 혁신적인 기술은 제품의 라이프사이클을 단축하고 시장 경계를 확대함으로써 여러 의료 부문의 비즈니스 기회를 창출하고 있습니다.

심혈관 질환, 암, 당뇨병, 호흡기 질환 등 질환은 인구의 사망률의 대부분을 차지하는 원인 또는 요인이 됩니다. 이러한 만성 질환 증가는 만성 질환의 조기 진단을 위한 면역단백질 검사를 증가시킵니다. 이러한 검사는 신속한 결과를 제공하고 곧 상태를 치료하는 데 도움이 됩니다.

또한, 기술의 진보, 인구간의 만성 질환의 유병률 증가, 질병의 조기 진단에 관한 의식의 높아짐이, 향후 일정 기간 시장을 견인하는 요인이 됩니다.

역학

진단 검사의 발전

면역 진단 검사의 발전으로 류마티스 관절염, 셀리악병 등과 같은 질병의 진단이 더욱 정확하고 신뢰할 수 있게 되었습니다. 예를 들어, 2023년 MDPI 저널에 따르면 미세유체 기술과 머신러닝의 결합은 신속하고 민감하며 선택적이고 정확하며 구현하기 쉬운 방식으로 여러 면역 바이오마커의 고처리량 검출을 효과적으로 달성하여 질병의 초기 단계 진단에 효과적으로 적용할 수 있는 면역 바이오마커의 첨단 현장 진단(POC) 검출 플랫폼으로 활용될 수 있습니다.

또 다른 보고서에서 Teengam 등은 HBV 검출을 위한 스마트폰 기반 휴대용 면역 감지 장치를 소개하였고, 임상 샘플에서 HBsAg의 검출 한계는 약 0.17 μg/mL이었습니다. 스마트폰을 활용함으로써 이 저비용 전기화학 면역센서는 고감도로 휴대가능한 실시간 결과를 제공하는 것 외에도 활용됩니다.

자가면역 질환 증가

자가면역질환은 약 10명 중 1명이 앓고 있습니다. 자가면역 질환은 1형 당뇨병, 류마티스 관절염, 전신성 홍반성 루푸스, 염증성 장 질환 등을 포함합니다. 그 부담은 개별 질병에 따라 속도가 다르며 시간이 지남에 따라 계속 증가하고 있습니다. 여러 자가면역 질환 사이에서 관찰되는 사회 경제적, 계절적, 지역적 격차는 질병의 병인에 환경 인자가 관여한다는 것을 시사합니다.

예를 들어, BMJ 저널에 따르면 2023년 자가면역질환은 전 세계 인구의 약 10%에 영향을 미치며, 여성의 13%와 남성의 7%가 관련되어 있습니다. 2040년까지 18세 이상의 미국 성인 중 약 7,840만 명(25.9%)이 의사의 진단을 받은 관절염(BRFSS)을 앓을 것으로 예상됩니다. 지난 수십 년 동안 주요 소아 만성 자가면역 질환의 발병률이 급격히 증가했습니다1. 제1형 당뇨병은 전 세계적으로 매년 2.4%, 유럽에서는 3-4%씩 발병률이 증가하는 것으로 추정됩니다.

높은 진단 검사 비용

팬데믹 이후 조기 질병 진단에 대한 수요가 증가하면서 진단 비용이 날로 치솟고 있습니다. 예를 들어, 사이언티픽 전자 도서관 온라인에 따르면 고령의 메디케어 수혜자 중 3분의 2가 두 가지 이상의 만성 질환을 앓고 있는 것으로 나타났습니다. 의료비 지출의 99%를 차지하지만, 그 이유는 병원 합병증의 위험이 높아져 비용이 증가하기 때문입니다. 2022년 3월부터 6월까지 6개의 민간 실험실에서 IFAT 및 ELISA 키트 가격을 제공했습니다. 소비자의 샘플당 평균 최종 비용은 IFAT의 경우 30.69달러, ELISA의 경우 4.88달러로 추정되었습니다. 이는 저소득 및 중산층 국가가 감당하기에는 너무 높은 가격이기 때문에 대부분의 사람들이 조기 진단을 건너뛰고 너무 늦은 시점에 말기 질환 치료를 받고 있습니다.

영문목차

Overview

Global Immunoprotein Diagnostic Testing Market reached US$ 9.4 billion in 2022 and is expected to reach US$ 15.8 billion by 2030 growing with a CAGR of 6.9% during the forecast period 2023-2030.

Immunoprotein diagnostic testing is a diagnostic procedure that detects the level of immunoproteins in the body to analyze specific proteins such as immunoglobulin and pre-albumin. With continuous technological development, the immunoprotein diagnostic testing market is booming globally. These innovative technologies shorten the life cycle of a product and expand the market's boundaries, creating several medical sector opportunities.

Conditions such as cardiovascular disease, cancer, diabetes, and respiratory disease were causes or contributing factors for most of the mortality cases among the population. Due to the rise in these chronic diseases, immunoprotein testing has increased for early diagnosis of chronic diseases. These provide a rapid result, which aids in treating the condition in no time.

Furthermore, technological advancements, the increasing prevalence of chronic diseases among the population, and growing awareness about early disease diagnosis are the factors that drive the market in the forthcoming period.

Dynamics

Rising Advancements in Diagnostic Testing

Advancements in immunodiagnostic testing make the diagnosis more accurate and reliable for the treatment of diseases such as rheumatoid arthritis, celiac disease, etc. For instance, according to MDPI Journals, in 2023, the combination of microfluidic technology and machine learning effectively achieved the high-throughput detection of multiple immune biomarkers in a rapid, sensitive, selective, accurate, and easy-to-implement manner to be exploited as an advanced point-of-care (POC) detection platform for immune biomarkers effectively applicable for the early-stage diagnosis of diseases.

In another report, Teengam et al. introduced a smartphone-based portable immunosensing device for the detection of HBV, and the limit of detection was about 0.17 µg/mL of HBsAg in the clinical samples. With the use of smartphones, this low-cost electrochemical immunosensor not only provides real-time results with high sensitivity and portability

Increasing Incidence of Autoimmune Diseases

Autoimmune diseases affect about one in ten individuals. Autoimmune diseases include type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. Their burden continues to increase over time, albeit at varying rates across individual conditions. The socio-economic, seasonal, and regional disparities observed among several autoimmune disorders implicate environmental factors in disease pathogenesis.

For instance, according to BMJ journals, in 2023, autoimmune diseases affect around 10% of the global population, with 13% of women and 7% of men involved. By 2040, an estimated 78.4 million (25.9%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis (BRFSS). During the last decades, the incidence of the major pediatric chronic autoimmune diseases has increased rapidly1. Type 1 Diabetes has had an estimated annual increase of incidence of 2.4% per year worldwide and 3-4% in Europe.

High Costs of Diagnostic Tests

The cost of diagnosis is skyrocketing every day as the demand for early disease diagnosis has increased post-pandemic. For instance, according to Scientific Electronic Library Online states that two-thirds of older Medicare beneficiaries had two or more chronic conditions. They accounted for 99% of health expenditures, but the reason for this is a more heightened risk of hospital complications that increase the costs. Between March and June 2022, the prices of IFAT and ELISA kits were provided by six private laboratories. The average final cost per sample for consumers was estimated at US$ 30.69 for IFAT and US$ 4.88 for ELISA. These are too high for low and middle-income countries to afford; hence, most people skip early diagnosis and get treated for an end-stage disease when it's too late.

Segment Analysis

The global immunoprotein diagnostic testing is segmented based on product type, test type, application, end-user and region.

The Enzyme-linked immunosorbent assay Segment Accounted for Approximately 35.7% of the Market Share

Enzyme-linked immunosorbent assay is expected to increase the market share as the accuracy has increased. A rise in product launches due to the demand for immunodiagnostic testing is observed. For instance, in July 2022 KSL Beutner Laboratories launched a first-to-market Indirect Immunofluorescence (IIF) serum blood test in the US that positively identifies laminin 332, an antigen associated with the chronic, debilitating autoimmune disease mucous membrane pemphigoid (MMP).

Furthermore, in August 2023, Thermo Fisher Scientific launched the EXENT Solution. The EXENT solution is a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. EXENT-iQ, is an intelligent and intuitive workflow software, including data review.

Geographical Analysis

North America accounted for Approximately 39.3% of the Market Share in 2022

North America is dominating the global immunoprotein diagnostic testing market and accounting for the largest market share, owing to rising incidences of chronic diseases, and rising to high demand for diagnostic systems. According to the Centers for Disease Control and Prevention (CDC), chronic diseases are the leading cause of death and disability in the United States. About 133 million Americans, i.e., 45% of the population, have at least one chronic disease. Chronic diseases are responsible for seven out of every 10 deaths in the U.S., killing more than 1.7 million Americans every year.

By 2025, chronic diseases will affect an estimated 164 million Americans. People with chronic conditions are the most frequent users of health care in the U.S. Accurate and fast diagnosis of such chronic diseases is needed to help diminish the high mortality rate. Immunoprotein diagnostic devices and reagents have proven to be extremely efficacious in the rapid detection of chronic disorders. Medical practitioners in the US and Canada have continuously focused on developing new immunoprotein testing.

COVID-19 Impact Analysis

The global pandemic has changed narratives around human health, compelling the medical research industry to develop new medical technologies and drugs. This factor reflects the pandemic's positive impact on the growth of the global immunoprotein diagnostic market. The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global immunoprotein diagnostic testing market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity

Lower capital expenditure is ongoing as businesses slow on investments, held back by inflation concerns and weaker demand. With slower growth and heightened inflation, expanded markets appear to enter a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path pose a real risk of the world experiencing more critical supply chain pain and manufacturing disruptions hindering the market.

By Product Type

Instruments and Kits
Radioimmunoassay
Immunoturbidity Assay
Immunoprotein Electrophoresis
Enzyme-linked immunosorbent assay
Chemiluminescence Assay
Fluorescence Assay
Colorimetric Assay
Others
Reagents
Others

By Test Type

Immunoglobulin Diagnostic Tests
C-Reactive Protein (CRP) Diagnostic Tests
Complement System Proteins Diagnostic Tests
Free Light Chain Diagnostic Tests
Haptoglobin Diagnostic Tests
Prealbumin Diagnostic Tests
Others

By Application

Autoimmune Disease Testing
Infectious Disease Testing
Oncology Testing
Allergy Testing
Toxicology Testing
Others

By End Users

Hospital and clinics
Diagnostic laboratories
Ambulatory Surgical Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

In July 2023, Anbio's AF-100S FIA Solution is a handheld point-of-care immunodiagnostic solution that provides rapid, accurate, and reliable results for a wide range of analytes. The Anbio AF-100S is set to transform the field of clinical diagnostics, empowering healthcare providers with a cost-effective and comprehensive solution that provides rapid, accurate, and reliable results for a wide range of analytes to provide faster diagnosis and better prognosis to patients
In May 2022, Omega Quant launched an HbA1c Test with a sample collection kit that allows for testing at home. This simple, safe, convenient test measures the amount of sugar (glucose) in the blood.
American Society of Tropical Medicine & Hygiene is conducting its 2023 annual meeting in Chicago, USA from October 18-22 where research Meets real-world experience. The meeting draws tropical medicine and global health professionals representing academia, foundations, government, not-for-profit organizations, non-governmental organizations, the private sector, the military, and private practice.

Competitive Landscape

The major global players in the immunoprotein diagnostic testing market include: Abbott Laboratories, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc, Danaher Corporation, F. Hoffmann-La Roche Ag, Enzo Biochem, Inc, Siemens AG, Ortho Clinical Diagnostics, Diasorin S.P.A, and Abcam Plc among others.

Why Purchase the Report?

To visualize the global immunoprotein diagnostic testing market based on product type, test type, application, end-user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of immunoprotein diagnostic testing market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global immunoprotein diagnostic testing market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Test Type
3.3. Snippet by Technology
3.4. Snippet by Application
3.5. Snippet by End User
3.6. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Advancements in Diagnostic Testing
- 4.1.2. Increasing Incidence of Autoimmune Diseases
- 4.1.3. Restraints
  - 4.1.3.1. High Costs of Diagnostic Tests
- 4.1.4. Opportunity
- 4.1.5. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Instruments and Kits
- 7.2.1. Radioimmunoassay
- 7.2.2. Immunoturbidity Assay
- 7.2.3. Immunoprotein Electrophoresis
- 7.2.4. Enzyme-linked immunosorbent assay
- 7.2.5. Chemiluminescence Assay
- 7.2.6. Fluorescence Assay
- 7.2.7. Colorimetric Assay
- 7.2.8. Others
7.3. Reagents
7.4. Others

8. By Test Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 8.1.2. Market Attractiveness Index, By Test Type
8.2. Immunoglobulin Diagnostic Tests
8.3. C-Reactive Protein (CRP) Diagnostic Test
8.4. Complement System Proteins Diagnostic Test
8.5. Free Light Chain Diagnostic Tests
8.6. Haptoglobin Diagnostic Tests
8.7. Prealbumin Diagnostic Tests
8.8. Others

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By
- 9.1.2. Market Attractiveness Index, By Application
9.2. Autoimmune Disease Testing
9.3. Infectious Disease Testing
9.4. Oncology Testing
9.5. Allergy Testing
9.6. Toxicology Testing
9.7. Others

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals and Clinics
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic laboratories
10.4. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.8.1. U.S.
  - 11.2.8.2. Canada
  - 11.2.8.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.8.1. Germany
  - 11.3.8.2. UK
  - 11.3.8.3. France
  - 11.3.8.4. Italy
  - 11.3.8.5. Russia
  - 11.3.8.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.8.1. Brazil
  - 11.4.8.2. Argentina
  - 11.4.8.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.8.1. China
  - 11.5.8.2. India
  - 11.5.8.3. Japan
  - 11.5.8.4. Australia
  - 11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Abbott Laboratories
- 13.1.1. Company Overview
- 13.1.2. Product Type Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Thermo Fisher Scientific Inc
13.3. Bio-Rad Laboratories, Inc
13.4. Danaher Corporation
13.5. F. Hoffmann-La Roche Ag
13.6. Enzo Biochem, Inc
13.7. Siemens AG
13.8. Ortho Clinical Diagnostics
13.9. Diasorin S.P.A
13.10. Abcam Plc

LIST NOT EXHAUSTIVE

14. Appendix

14.1. About Us and Services
14.2. Contact Us